Retatrutide Delivers Substantial Weight Loss In Type 2 Diabetes

TL;DR

Prime Big Deal Days · Oct 6–7Offer from Amazon

Get health and wellness essentials delivered free — and shop member deals

• Fast, free delivery on millions of items
• Access to Prime Big Deal Days deals on October 6–7
• Prime Video, Amazon Music and more included

Start your free Prime trial →Free trial for eligible customers · Cancel anytime

As an affiliate, we earn on qualifying purchases.Hide

In the phase III TRIUMPH-2 trial, adults with obesity and type 2 diabetes lost an average of 11.9% to 18.8% of their body weight after 80 weeks on retatrutide, depending on dose, compared with 5.1% on placebo. The investigational drug also improved blood sugar measures; its safety, comparisons with other medicines and potential FDA review remain open questions.

The investigational drug retatrutide produced average weight loss of up to 18.8% after 80 weeks among adults with obesity and type 2 diabetes in the phase III TRIUMPH-2 trial, compared with 5.1% with placebo. The study also found improvements in blood sugar control, adding evidence about a potential treatment for people who often lose less weight than people without diabetes.

Among 1,152 participants, average weight change in the trial’s treatment-regimen analysis was a loss of 11.9% with the 4-mg dose, 16.8% with 9 mg and 18.8% with 12 mg. The placebo group lost 5.1%. In pounds, the reported average losses were 28.4, 40.3 and 45.6 pounds in the three retatrutide groups, respectively, versus 12.8 pounds with placebo. These figures describe the 80-week study period and should not be read as results beyond the trial.

In a separate efficacy analysis that assumed participants took treatment as intended and did not experience events affecting the analysis, weight loss reached 20.8% with the highest dose. Juan P. Frias, who presented the findings, said more than half of participants in that analysis lost over 15% of their body weight. That estimate uses a different analysis method from the treatment-regimen figures and is not the same result.

Retatrutide also lowered HbA1c, a measure of average blood sugar. Mean reductions from baseline ranged from 1.38 to 1.50 percentage points across the drug doses, compared with 0.45 points on placebo. Up to 40% of participants receiving retatrutide reached normoglycemia, defined in the report as HbA1c below 5.7%. The study also reported improvements in several other cardiometabolic measures, including waist circumference, triglycerides, non-HDL cholesterol and high-sensitivity C-reactive protein.

Potential Gains in Diabetes Care

The findings address a treatment gap for people managing both obesity and type 2 diabetes. The study authors described a need for more effective weight reduction in this group. In the prior trial results cited in the report, high-dose semaglutide was associated with average weight loss of 13.2% and tirzepatide with 15.7% among people with diabetes. Those figures come from separate trials, however, and do not establish how the drugs would compare in a direct test.

Substantial weight loss alongside lower HbA1c could matter to patients and clinicians weighing options for diabetes and obesity care. But TRIUMPH-2 tested retatrutide against placebo, not another active medicine, and it does not establish that the drug will be approved or show how its benefits and risks compare with available treatments. Retatrutide remains investigational and is not an approved treatment.

How TRIUMPH-2 Was Conducted

TRIUMPH-2 was a double-blind, placebo-controlled phase III trial at 92 medical and research centers in eight countries. Participants received once-weekly injections of retatrutide or placebo. Eligible adults had a body mass index of at least 27, type 2 diabetes with HbA1c between 6.5% and 10.5%, and stable background glucose-lowering treatment for at least 90 days before screening. They also had a history of trying diet-based weight loss.

At the start of the study, participants’ average BMI was 38.2 and average HbA1c was 7.71%. Median obesity duration was 21 years, and median diabetes duration was 5.6 years. Frias, of the Los Angeles Institute for Metabolic Research, said weight loss among people with diabetes has generally been lower than among people without diabetes, regardless of the method used. The investigators said the weight loss in this trial had previously been observed with anti-obesity drugs mainly in people without diabetes.

Retatrutide acts on three hormone pathways: GIP, GLP-1 and glucagon. Frias said engaging these pathways may help explain the weight-loss results. That is an explanation offered by the presenter, not proof from this trial that any single pathway caused the observed difference.

“We know that people with type 2 diabetes lose less weight than people without diabetes.”

— Juan P. Frias, MD, who presented the findings

Safety and Comparisons Still Open

The trial found that gastrointestinal events, mainly nausea, diarrhea and constipation, were the most frequent adverse events. Discontinuation because of adverse events ranged from 3% to 11% in the retatrutide groups, compared with 5% on placebo; discontinuation specifically due to gastrointestinal symptoms was 0% to 2% with retatrutide and 1% with placebo. Hypotension and dysesthesia occurred more often in the retatrutide groups.

Seven participants died during the trial, including participants in several treatment groups. The investigators judged all deaths unrelated to the study interventions. The report also identified limitations: there was no active comparator, and the trial did not measure body composition, leaving the relative amounts of fat and lean mass lost unknown. The available results do not resolve how retatrutide’s benefits and risks compare directly with other medicines, or what longer-term outcomes may be.

These are clinical trial findings, not personal medical guidance. Treatment decisions should be made with a qualified health professional, and retatrutide is not currently an approved treatment.

FDA Submission Planned for 2027

Eli Lilly said it plans to submit data to the U.S. Food and Drug Administration in early 2027. A planned submission is not an approval, and the source material does not specify when the company expects a regulatory decision. Further evidence and the FDA’s review would be needed before retatrutide could be considered an approved option.

For now, the reported results add phase III evidence on weight and blood sugar changes over 80 weeks. Future regulatory materials may provide more detail about the benefit-risk profile and how the findings should be interpreted, including the questions left open by the lack of an active comparator and body-composition data.

Key Questions

How much weight did participants lose on retatrutide?

At 80 weeks, average weight loss in the treatment-regimen analysis ranged from 11.9% on 4 mg to 18.8% on 12 mg. The placebo group lost 5.1% on average.

Did retatrutide improve blood sugar measures?

Yes. Mean HbA1c fell by 1.38 to 1.50 percentage points across retatrutide doses, compared with 0.45 points with placebo. Up to 40% of participants taking retatrutide reached the study’s normoglycemia threshold of HbA1c below 5.7%.

Is retatrutide approved for treating diabetes or obesity?

No. Retatrutide is investigational. Eli Lilly said it plans to submit data to the FDA in early 2027; that plan does not mean the drug has been approved.

What side effects were reported in the trial?

Gastrointestinal events, particularly nausea, diarrhea and constipation, were the most frequent adverse events. Hypotension and dysesthesia occurred more often in retatrutide groups. The trial report said all seven deaths were judged unrelated to the study interventions.

How does retatrutide compare with other weight-loss drugs?

The report cited average losses of 13.2% with high-dose semaglutide and 15.7% with tirzepatide in prior diabetes trial data. Those were separate trials, not a head-to-head comparison with retatrutide, so the figures do not establish which drug is more effective.

Source: rss